Literature DB >> 17220801

A pooled analysis of posttransplant survival following combined heart-liver transplantation.

Neal R Barshes1, Ian W Udell, David L Joyce, Robert E Southard, Christine A O'Mahony, John A Goss.   

Abstract

Because no single center has accumulated a large experience with this complex operation, the effectiveness of combined orthotopic heart transplantation (OHT) and orthotopic liver transplantation (OLT) in achieving long-term survival has been unknown. Cases of OHT-OLT were pooled from a U.S. transplant recipient registry and from previously published literature. Aggregate data from these sources was used for survival analysis. Thirty-six patients having undergone OHT-OLT were listed in the national registry; the one- and five-year patient survival rates of these patients were 88% and 78%, respectively. Many patients remain alive at 8+ years after transplantation. An analysis of the pooled results of previously-published cases estimated a one-year patient survival rate of 84%. In selected disease processes, OHT-OLT can correct underlying metabolic deficiencies. While rarely indicated, OHT-OLT is a successful treatment for patients with end-stage heart and liver disease, with survival comparable to that seen after isolated orthotopic heart or orthotopic liver transplantation.

Entities:  

Mesh:

Year:  2007        PMID: 17220801     DOI: 10.1097/01.tp.0000243731.29657.87

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  2 in total

Review 1.  Combined heart-liver transplantation: Indications, outcomes and current experience.

Authors:  Eliza W Beal; Khalid Mumtaz; Don Hayes; Bryan A Whitson; Sylvester M Black
Journal:  Transplant Rev (Orlando)       Date:  2016-07-17       Impact factor: 3.943

2.  Simultaneous Versus Sequential Heart-liver Transplantation: Ideal Strategies for Organ Allocation.

Authors:  A Justin Rucker; Kevin L Anderson; Michael S Mulvihill; Babatunde A Yerokun; Andrew S Barbas; Matthew G Hartwig
Journal:  Transplant Direct       Date:  2018-12-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.